A detailed history of Balyasny Asset Management LLC transactions in Vericel Corp stock. As of the latest transaction made, Balyasny Asset Management LLC holds 6,173 shares of VCEL stock, worth $348,774. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,173
Previous 34,885 82.3%
Holding current value
$348,774
Previous $1.6 Million 83.75%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$42.25 - $53.56 $1.21 Million - $1.54 Million
-28,712 Reduced 82.3%
6,173 $260,000
Q2 2024

Aug 14, 2024

BUY
$41.71 - $52.9 $1.46 Million - $1.85 Million
34,885 New
34,885 $1.6 Million
Q3 2023

Nov 14, 2023

SELL
$31.69 - $39.25 $808,506 - $1 Million
-25,513 Reduced 64.28%
14,175 $475,000
Q2 2023

Aug 14, 2023

BUY
$29.0 - $38.37 $328,802 - $435,039
11,338 Added 39.99%
39,688 $1.49 Million
Q1 2023

May 15, 2023

BUY
$23.85 - $31.34 $676,147 - $888,489
28,350 New
28,350 $831,000
Q1 2020

May 15, 2020

SELL
$7.25 - $19.22 $1.2 Million - $3.18 Million
-165,661 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$13.77 - $19.2 $1.29 Million - $1.8 Million
93,803 Added 130.54%
165,661 $2.88 Million
Q3 2019

Nov 14, 2019

SELL
$14.93 - $19.83 $1.82 Million - $2.42 Million
-122,056 Reduced 62.94%
71,858 $1.09 Million
Q2 2019

Aug 14, 2019

SELL
$15.01 - $18.89 $285,835 - $359,722
-19,043 Reduced 8.94%
193,914 $3.66 Million
Q1 2019

May 15, 2019

BUY
$16.23 - $20.29 $3 Million - $3.75 Million
184,752 Added 655.03%
212,957 $3.73 Million
Q4 2018

Feb 14, 2019

BUY
$10.77 - $18.44 $303,767 - $520,100
28,205 New
28,205 $491,000

Others Institutions Holding VCEL

About Vericel Corp


  • Ticker VCEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,178,000
  • Market Cap $2.67B
  • Description
  • Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for t...
More about VCEL
Track This Portfolio

Track Balyasny Asset Management LLC Portfolio

Follow Balyasny Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balyasny Asset Management LLC with notifications on news.